Literature DB >> 21106708

Glucose-dependent insulinotropic polypeptide (GIP) induces calcitonin gene-related peptide (CGRP)-I and procalcitonin (Pro-CT) production in human adipocytes.

Katharina Timper1, Jean Grisouard, Tanja Radimerski, Kaethi Dembinski, Ralph Peterli, Andreas Häring, Daniel M Frey, Henryk Zulewski, Ulrich Keller, Beat Müller, Mirjam Christ-Crain.   

Abstract

CONTEXT: Increased plasma levels of glucose-dependent insulinotropic polypeptide (GIP), calcitonin CT gene-related peptide (CGRP)-I, and procalcitonin (Pro-CT) are associated with obesity. Adipocytes express functional GIP receptors and the CT peptides Pro-CT and CGRP-I. However, a link between GIP and CT peptides has not been studied yet.
OBJECTIVE: The objective of the study was the assessment of the GIP effect on the expression and secretion of CGRP-I and Pro-CT in human adipocytes, CGRP-I and CT gene expression in adipose tissue (AT) from obese vs. lean subjects, and plasma levels of CGRP-I and Pro-CT after a high-fat meal in obese patients. DESIGN AND PARTICIPANTS: Human preadipocyte-derived adipocytes, differentiated in vitro, were treated with GIP. mRNA expression and protein secretion of CGRP-I and Pro-CT were measured. Human CGRP-I and CT mRNA expression in AT and CGRP-I and Pro-CT plasma concentrations were assessed.
RESULTS: Treatment with 1 nm GIP induced CGRP-I mRNA expression 6.9 ± 1.0-fold (P < 0.001 vs. control) after 2 h and CT gene expression 14.0 ± 1.7-fold (P < 0.001 vs. control) after 6 h. GIP stimulated CGRP-I secretion 1.7 ± 0.2-fold (P < 0.05 vs. control) after 1 h. In AT samples of obese subjects, CGRP-I mRNA expression was higher in sc AT (P < 0.05 vs. lean subjects), whereas CT expression was higher in visceral AT (P < 0.05 vs. lean subjects). CGRP-I plasma levels increased after a high-fat meal in obese patients.
CONCLUSION: GIP induces CGRP-I and CT expression in human adipocytes. Therefore, elevated Pro-CT and CGRP-I levels in obesity might result from GIP-induced Pro-CT and CGRP-I release in AT and might be triggered by a high-fat diet. How these findings relate to the metabolic complications of obesity warrants further investigations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106708     DOI: 10.1210/jc.2010-1324

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue.

Authors:  Jonathan E Campbell; Jacqueline L Beaudry; Berit Svendsen; Laurie L Baggio; Andrew N Gordon; John R Ussher; Chi Kin Wong; Fiona M Gribble; David A D'Alessio; Frank Reimann; Daniel J Drucker
Journal:  Diabetes       Date:  2022-05-01       Impact factor: 9.337

Review 2.  Role of calcitonin gene-related peptide in energy metabolism.

Authors:  William Gustavo Lima; Gleuber Henrique Marques-Oliveira; Thaís Marques da Silva; Valéria Ernestânia Chaves
Journal:  Endocrine       Date:  2017-09-07       Impact factor: 3.633

Review 3.  Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future.

Authors:  Philipp Schuetz; Werner Albrich; Beat Mueller
Journal:  BMC Med       Date:  2011-09-22       Impact factor: 8.775

4.  Differential effects of Calca-derived peptides in male mice with diet-induced obesity.

Authors:  Alexander Bartelt; Anke Jeschke; Brigitte Müller; Isabella Gaziano; Michelle Morales; Timur Yorgan; Timo Heckt; Markus Heine; Robert F Gagel; Ronald B Emeson; Michael Amling; Andreas Niemeier; Jörg Heeren; Thorsten Schinke; Johannes Keller
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

Review 5.  Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.

Authors:  Jonathan E Campbell
Journal:  Mol Metab       Date:  2020-12-05       Impact factor: 7.422

Review 6.  A compendium of G-protein-coupled receptors and cyclic nucleotide regulation of adipose tissue metabolism and energy expenditure.

Authors:  Ryan P Ceddia; Sheila Collins
Journal:  Clin Sci (Lond)       Date:  2020-03-13       Impact factor: 6.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.